Clementia is charting a new course to develop effective new treatments for people who have none.
The company is developing its lead candidate palovarotene, a novel RARγ agonist, to treat Fibrodysplasia Ossificans Progressiva (FOP), Multiple Osteochondromas (MO), and other diseases.
We believe that palovarotene holds significant potential for individuals with debilitating bone and other diseases with high unmet medical need.
Our name, Clementia, is derived from the Latin word for compassion or empathy – a concept that inspires everything we do.
Contact:
Address: 4150 Ste-Catherine Street West, Suite 550, Montreal, QC H3Z 2Y5, Canada
Tel.: +1 (514) 940-3600
Website: http://clementiapharma.com/